New investment to biotech company Natimmune  

Existing investors pump DKK 35 million into Danish biotech company to drive development of promising drug for cancer patients

Biotech company Natimmune has received a DKK 35 million (USD 5.6 million) investment from existing investors including Novo A/S, Danish Innovation Investment, the Danish Fund for Industrial Growth and the Employees Capital Pension Fund. The new investment will be used for reaching a number of milestones in developing the company's main product, Mannose Binding Lectin (MBL), which is being developed for the prevention of infections in cancer patients during chemotherapy.


During H1 2004 Natimmune anticipates the need to raise further capital. At that time a scientific article will have been written which is expected to support the development of recombinant MBL protein. Natimmune is based in Symbion Science Park in Copenhagen and currently employs 20 people. The news is reported by BiotechDenmark and on Natimmune's website.


Link > Natimmune

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×